Ingrid Eshun-Wilson1, Jantjie J Taljaard, Jean B Nachega. 1. Centre for Infectious Diseases, Stellenbosch University, Parow, 7505, Cape Town South Africa; Department of Epidemiology and Biostatistics, University of San Francisco, California, 41097, USA.
Abstract
STUDY BACKGROUND: Poor CD4 T-lymphocyte responses to anti-retroviral treatment (ART) are associated with increased HIV disease progression and mortality. In sub-Saharan Africa a substantial proportion of HIV infected patients are co-infected with TB. This study evaluated the effect of active TB presenting after ART initiation on immunological responses to ART. METHODS: A retrospective cohort study was conducted of patients initiated on ART in a South African academic hospital between 1 January 2004 and 15 May 2008. Changes in CD4 T-lymphocyte count, virological suppression and incident TB episodes occurring in the first year of ART were assessed. Sub-optimal CD4 responses were defined as 'failure to increase CD4 T-lymphocyte count by 50cells/μl at 6 month on ART'. RESULTS: The cohort for analysis included 691 patients. 141 (20.4%) had sub-optimal CD4 responses at 6 months on ART. 49 patients (7.1%) developed incident TB within the first 12 months of ART. After adjustment for age, sex, baseline CD4 count and detectable viral load, patients with incident TB were found to have a 2.20 times greater odds of a sub-optimal CD4 response at 6 month of ART as compared to those who were TB free (95%CI: 1.14-4.23). CONCLUSION: Incident TB was associated with a poor CD4 response during early ART in this cohort. Although the direction of causality cannot be determined from these data, these findings provide additional support for the initiation of ART at higher CD4 counts.
STUDY BACKGROUND: Poor CD4 T-lymphocyte responses to anti-retroviral treatment (ART) are associated with increased HIV disease progression and mortality. In sub-Saharan Africa a substantial proportion of HIV infectedpatients are co-infected with TB. This study evaluated the effect of active TB presenting after ART initiation on immunological responses to ART. METHODS: A retrospective cohort study was conducted of patients initiated on ART in a South African academic hospital between 1 January 2004 and 15 May 2008. Changes in CD4 T-lymphocyte count, virological suppression and incident TB episodes occurring in the first year of ART were assessed. Sub-optimal CD4 responses were defined as 'failure to increase CD4 T-lymphocyte count by 50cells/μl at 6 month on ART'. RESULTS: The cohort for analysis included 691 patients. 141 (20.4%) had sub-optimal CD4 responses at 6 months on ART. 49 patients (7.1%) developed incident TB within the first 12 months of ART. After adjustment for age, sex, baseline CD4 count and detectable viral load, patients with incident TB were found to have a 2.20 times greater odds of a sub-optimal CD4 response at 6 month of ART as compared to those who were TB free (95%CI: 1.14-4.23). CONCLUSION: Incident TB was associated with a poor CD4 response during early ART in this cohort. Although the direction of causality cannot be determined from these data, these findings provide additional support for the initiation of ART at higher CD4 counts.
Authors: C Marimoutou; G Chêne; P Mercié; D Neau; S Farbos; P Morlat; J Ceccaldi; F Dabis Journal: J Acquir Immune Defic Syndr Date: 2001-06-01 Impact factor: 3.731
Authors: S J Kony; A A Hane; B Larouzé; A Samb; S Cissoko; P S Sow; M Sané; M Maynart; G Diouf; J F Murray Journal: J Infect Date: 2000-09 Impact factor: 6.072
Authors: S Grabar; V Le Moing; C Goujard; C Leport; M D Kazatchkine; D Costagliola; L Weiss Journal: Ann Intern Med Date: 2000-09-19 Impact factor: 25.391
Authors: Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe Journal: PLoS One Date: 2010-05-07 Impact factor: 3.240
Authors: Suely H Tuboi; Martin W G Brinkhof; Matthias Egger; Roslyn A Stone; Paula Braitstein; Denis Nash; Eduardo Sprinz; François Dabis; Lee H Harrison; Mauro Schechter Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Felipe García; Elisa de Lazzari; Montserrat Plana; Pedro Castro; Gabriel Mestre; Meritxell Nomdedeu; Emilio Fumero; Esteban Martínez; Josep Mallolas; José L Blanco; José M Miró; Tomás Pumarola; Teresa Gallart; José M Gatell Journal: J Acquir Immune Defic Syndr Date: 2004-06-01 Impact factor: 3.731